0GWJ Stock Chart & Stats
€46.80
€0.40(1.22%)
At close: 4:00 PM EST
€46.80
€0.40(1.22%)
Day’s Range― - ―
52-Week Range€40.20 - €62.00
Previous CloseN/A
Volume1.00
Average Volume (3M)243.00
Market Cap
€877.13M
Enterprise Value€882.45M
Total Cash (Recent Filing)€51.59M
Total Debt (Recent Filing)€9.90M
Price to Earnings (P/E)19.3
Beta0.52
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.79
Shares Outstanding16,307,580
10 Day Avg. Volume281
30 Day Avg. Volume243
Financial Highlights & Ratios
PEG Ratio2.92
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€71.50Price Target Upside52.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.86
Revenue Forecast (FY)€331.00M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthThe sustained increase in revenue across multiple annual periods indicates continuing demand for Clinica Baviera’s ophthalmology services and expanding business activity. Positive TTM growth suggests this trajectory remains relevant, supporting clinic utilization, operating scale, and future earnings potential over the next several quarters.
Strong ProfitabilityConsistently strong net margins demonstrate that the clinic network converts service revenue into meaningful earnings, providing resilience and internal funding capacity. Continued profitability also supports investment in clinical capacity and reinforces the company’s ability to sustain operations while pursuing further growth.
Improved Balance SheetMaterial deleveraging improves financial flexibility by reducing the burden of debt service and leaving more capacity for clinic investment, dividends, or resilience during weaker demand. The accompanying increase in equity and assets strengthens the balance sheet, provided the recent improvement persists.
Bears Say
Margin VolatilityRecent margin movement introduces uncertainty around how reliably revenue growth will translate into operating earnings. Whether driven by service mix, accounting differences, or cost and pricing pressure, sustained volatility could reduce earnings predictability and limit the benefit of continued top-line expansion.
Moderate Free Cash Flow ConversionPositive free cash flow supports the business, but moderate conversion means a meaningful portion of reported profit is absorbed by reinvestment needs or working-capital movements. If this pattern persists, internally generated cash may be less available for expansion, shareholder returns, or balance-sheet strengthening.
Deleveraging DurabilityThe current low-leverage position is favorable, but its durability remains an important consideration because earlier periods showed materially higher debt relative to equity. A reversal could reduce financial flexibility and increase exposure to financing costs, weakening the balance-sheet advantage currently supporting the company.
Clinica Baviera News
0GWJ FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Clinica Baviera, SA lowest share price was €40.20 and its highest was €62.00 in the past 12 months.
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is €877.13M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Nov 05, 2026 which is in 7 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Jul 29, 2026. The company reported €0.747 earnings per share for the quarter.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Undervalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA does not currently pay dividends.
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of €0.747 in its last earnings report. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in GB:0GWJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clínica Baviera, S.A., a medical company, provides ophthalmologic medicine services in Spain, Germany, and rest of Europe. The company offers refractive, presbyopia, and cataract surgeries; and oculoplastia, corneal disease, dry eye, strabismus, pediatric ophthalmology, glaucoma, neuro-ophthalmological, disorders, and blepharoplasty treatments. It also provides external and internal consultations, surgery treatments, and rehabilitation services. The company was formerly known as Clínica Oftalmológica Baviera, S.L. and changed its name to Clínica Baviera, S.A. in 2000. Clínica Baviera, S.A. was incorporated in 1992 and is based in Madrid, Spain. Clínica Baviera, S.A. is a subsidiary of Aier Eye International (Europe), S.L.U.
0GWJ Stock 12 Month Forecast
Average Price Target
€71.50
▲(52.78% Upside)